Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal

Behavioural Brain Research

Volumn 144, Issue 1-2, 2003, Pages 25-35

  Maldonado, C ^a   Cauli, O ^a   Rodriguez Arias M ^a   Aguilar, M A ^a   Minarro J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

CPA; Memantine; MK 801; Morphine; Physical syndrome; Withdrawal

Indexed keywords

DIZOCILPINE; MEMANTINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADAPTIVE BEHAVIOR; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EVALUATION; MALE; MORPHINE ADDICTION; MOTIVATION; MOUSE; NONHUMAN; OPIATE ADDICTION; PLACE PREFERENCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; WITHDRAWAL SYNDROME;

EID: 0042889252     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00044-5     Document Type: Article

References (87)

1. Acquas E., Carboni E., Leone P., Di Chiara G. SCH 23390 blocks drug-conditioned place-preference and place aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade. Psychopharmacology. 99:1989;151-155.
2. Bardo M.T. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit. Rev. Neurobiol. 12:1998;37-67.
3. Beardsley P.M., Hayes B.A., Balster R.L. The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J. Pharmacol. Exp. Ther. 252:1990;953-959.
4. Beart P.M., Lodge D. Chronic administration of MK-801 and the NMDA receptor: further evidence for reduced sensitivity of the primary acceptor site from studies with the cortical wedge preparation. J. Pharm. Pharmacol. 42:1990;354-355.
5. Beninger R.J., Miller R. Dopamine D1-like receptors and reward-related incentive learning. Neurosci. Biobehav. Rev. 22:1998;335-345.
6. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology. 157:2001;1-10.
7. Blokhina E.A., Sukhotina I.A., Bespalov A.Y. Pretreatment with morphine potentiates naloxone-conditioned place aversion in mice: effects of NMDA receptor antagonists. Eur. J. Pharmacol. 406:2000;227-232.
8. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166:1989;591-592.
9. Bozarth M.A., Wise R.A. Heroin reward is dependent on a dopaminergic substrate. Life Sci. 29:1981;1881-1886.
10. Brain PF, McAllister KH, Wamsley SV. Drug effects on social behaviors. In: Boulton AA, Baker GB, Greenshaw AJ, editors. Methods in ethopharmacology. Psychopharmacology (series: Neuromethods, vol. 13). Clifton, NJ: Human Press; 1989. p. 687-739.
11. Brent P.J., Chahl L.A. Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma bindings sites. Eur. Neuropsychopharmacol. 3:1993;23-32.
12. Broseta I., Rodríguez-Arias M., Stinus L., Miñarro J. Ethological analysis of morphine withdrawal with different dependence programs in male mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26(2):2002;335-347.
13. Cappendijk S.L., de Vries R., Dzoljic M.R. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur. Neuropsychopharmacol. 3:1993;111-116.
14. Carlezon W.A., Kosten T.A., Nestler E.J. Behavioral interactions caused by combined administration of morphine and MK 801 in rats. Psychopharmacology. 151:2000;261-272.
15. Corbett D. Possible abuse potential of the NMDA antagonist MK-801. Behav. Brain Res. 34:1989;239-246.
16. Danysz W., Essmann U., Bresink I., Rolf W. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav. 48:1994;111-118.
17. Danysz W., Parsons C.G., Kornhuber J., Scmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
18. Del Pozo E., Barrios M., Baeyens J.M. The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice. Psychopharmacology. 125:1996;209-213.
19. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 38:1995;95-137.
20. Ettenberg A., MacConell L.A., Geist T.D. Effects of haloperidol in a response-reinstatement model of heroin relapse. Psychopharmacology. 124:1996;205-210.
21. Fernandez-Espejo E., Cador M., Stinus L. Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: a newly-developed "etho-score" Psychopharmacology. 122:1995;122-130.
22. Foster A.C., Wong W.H.F. The novel anticonvulsant (+)-MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br. J. Pharmacol. 91:1987;403-409.
23. Gellert V.F., Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 205:1978;536-546.
24. Glick S.D., Cox R.D. Dopaminergic and cholinergic influences on morphine self-administration in rats. Res. Commun. Chem. Pathol. Pharmacol. 12:1975;17-24.
25. Gonzalez P., Cabello P., Germany A., Norris B., Contreras E. Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur. J. Pharmacol. 332:1997;257-262.
26. Haberny K.A., Young G.A. Interactive effects of MK-801 and morphine on EEG, EEG power spectra and behaviour in rats: II. Morphine dependence. Eur. J. Pharmacol. 261:1994;11-16.
27. Hand T.H., Franklin K.B. 6-OHDA lesions of the ventral tegmental area block morphine-induced but not amphetamine-induced facilitation of self-stimulation. Brain Res. 328:1985;233-241.
28. Herberg L.J., Rose I.C. The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward. Psychopharmacology. 99:1989;87-90.
29. Herman B.H., Vocci F., Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology. 13:1995;269-293.
30. Hesselink M.B., Smolders H., De Boer A.G., Breimer D.D., Danysz W. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration. Behav. Pharmacol. 10:1999;85-98.
31. Higgins G.A., Nguyen P., Sellers E.M. The NMDA antagonist dizocilpine (MK801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci. 50:1992;167-172.
32. Higgins G.A., Sellers E.M. Antagonist-precipitated opioid withdrawal in rats: evidence for dissociations between physical and motivational signs. Pharmacol. Biochem. Behav. 48:1994;1-8.
33. Hong M., Milne B., Jhamandas K. Evidence for the involvement of excitatory amino acid pathways in the development of precipitated withdrawal from acute and chronic morphine: an in vivo voltammetric study in the rat locus coeruleus. Brain Res. 623:1993;131-141.
34. Kemp J.A., Foster A.C., Wong E.H.F. Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci. 10:1987;294-299.
35. Kim H.S., Jang C.G., Park W.K. Inhibition by MK-801 of morphine-induced conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice. Pharmacol. Biochem. Behav. 55:1996;11-17.
36. 3H ]dibenzocycloalkenimine (MK-801) to the N-methyl-D-aspartate (NMDA) receptor and its therapeutic implication FEBS Lett. 230:1988;167-170.
37. Koob G.F. Drug of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
38. Kornhuber J., Bormann J., Retz W., Hubers M., Riederer P. Memantine displaces [3H]-MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166:1989;589-590.
39. Kornhuber J., Weller M. Psychotogenicity N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry. 41:1997;135-144.
40. Kotlinska J., Biala G. Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Pol. J. Pharmacol. 52:2000;179-185.
41. Koyuncuoglu H., Saydam B. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int. J. Ciln. Pharmacol. Ther. Toxicol. 28:1990;147-152.
42. Koyuncuoglu H., Güngor M., Sagduyu H., Aricioglu F. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Pharmacol. Biochem. Behav. 35:1990;829-832.
43. Koyuncuoglu H., Ariocioglu G. Previous chronic blockade of NMDA receptors intensifies morphine dependence in rats. Pharmacol. Biochem. Behav. 39:1991;575-579.
44. Lannes B., Bernard V., Bloch B., Micheletti G. Chronic treatment with dizocilpine maleate increases the number of striatal neurons expressing the d-2 receptor gene. Neuroscience. 65:1995;431-438.
45. Leone P., Di Chiara G. Blockade of D-1 receptors by SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning. Eur. J. Pharmacol. 135:1987;251-254.
46. 3H ]D-AP5, suggesting down-regulation of the cortical N-methyl-D-aspartate receptors Neuroscience. 30:1989;87-94.
47. Manning B.H., Mao J., Frenk H., Price D.D., Mayer D.J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 67:1996;79-88.
48. Manzanedo C., Aguilar M.A., Rodriguez-Arias M., Miñarro J. Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behav. Brain Res. 121:2001;189-197.
49. Mao J. NMDA and opioid receptors: their interactions in antinociception. Brain Res. Rev. 30:1999;289-304.
50. Marquis K.L., Piesla M.J., Muth E.A., Boast C.A. Effects of acute/ chronic MK-801 on naloxone-precipitated jumping in morphine-dependent mice. Soc. Neurosci. Abstr. 17:1991;331.
51. ω-monomethyl-L-arginine (NMMA) on morphine abstinence syndrome. Soc. Nurosci. Abstr. 19:1993;1461.
52. McLemore G., Kest B., Inturrisi C.E. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. Brain Res. 778:1997;120-126.
53. Micheletti G., Lannes B., Haby C., Borrelli E., Kempf E., Warter J.M.et al. Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum. Mol. Brain Res. 14:1992;363-368.
54. Nestler E.J. Under siege: the brain on opiates. Neuron. 16:1996;897-900.
55. Ozawa S., Kamiya H., Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54:1998;581-618.
56. Parsons C.G., Panchenko V.A., Pinchenko V.O., Tsyndrenko Ay., Krishtal O.A. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur. J. Neurosci. 8:1996;446-454.
57. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;735-767.
58. Phillips A.G., Broekkamp C.L., Fibiger H.C. Strategies for studying the neurochemical substrates of drug reinforcement in rodents. Prog. Neuropsychopharmacol. Biol. Psychiatry. 7:1983;585-590.
59. Popik P., Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53:1996;791-797.
60. Popik P., Layer R.T., Fossom L., Benveniste M., Getter-Douglas B., Witkin J.M.et al. NMDA antagonist properties of the putative anti-addictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275:1995;753-760.
61. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 280:1997;854-865.
62. Pulvirenti L., Maldonado-Lopez R., Koob G.F. NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res. 594:1992;327-330.
63. Pulvirenti L., Koob G.F. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol. Sci. 15:1994;374-379.
64. Ranaldi R., Munn E., Neklesa T., Wise R.A. Morphine and amphetamine sensitisation in rats demonstrated under moderate- and high-dose NMDA receptor blockade with MK-801 (dizocilpine). Psychopharmacology. 151:2000;192-201.
65. Rasmussen K., Fuller R.W., Stockton M.E., Perry K.W., Swinford R.M., Ornstein P.L. NMDA receptor antagonists suppress behaviours but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol. 197:1991;9-16.
66. Rasmussen K. The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Neuropsychopharmacology. 13:1995;295-300.
67. Rosen MI, McMhon TH, Woods S, Pearsall HR, Kosten TR. The effect of dextromethorphan on naloxone-precipitated opiate withdrawal. In: Paper presented at the NIDA technical review. The role of glutamatergic system in the development of opiate addiction. Gaithersburg, MD, October 17-18; 1995.
68. Salamone J.D. The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. J. Neurosci. Met. 64:1996;137-149.
69. Satoh M., Zieglgansberger W., Herz A. Supersensitivity of cortical neurones of the rat to acetylcholine and L-glutamate following chronic morphine treatment. Naunyn Schmiedebergs Arch. Pharmacol. 293:1976;101-103.
70. Semenova S., Danysz W., Bespalov A. Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice. Eur. J. Pharmacol. 378:1999;1-8.
71. Sepulveda M.J., Hernandez L., Rada P., Tucci S., Contreras E. Effect of precipitated withdrawal on extracellular glutamate and aspartate in the nucleus accumbens of chronically morphine-treated rats: an in vivo microdialysis study. Pharmacol. Biochem. Behav. 60:1998;255-262.
72. Shippenberg T.S., Bals-Kubik R., Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J. Pharmacol. Exp. Ther. 265:1993;53-59.
73. Spanagel R., Eibacher R., Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmacokinetic microdialysis study. Eur. J. Pharmacol. 262:1994;21-26.
74. Spyraki C., Fibiger H.C., Phillips A.G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology. 79:1983;278-283.
75. Sukhotina I.A., Bespalov A.Y. Effects of the NMDA receptor channel blockers memantine and MRZ 2/579 on morphine withdrawal-facilitated aggression in mice. Psychopharmacology. 149:2000;345-350.
76. Tanganelli S., Antonelli T., Morari M., Bianchi C., Beani L. Glutamate antagonists prevent morphine withdrawal in mice and guinea-pigs. Neurosci. Lett. 122:1991;270-272.
77. ω-monomethyl-L-arginine and MK-801 on the abstinence syndrome in morphine-dependent mice. Brain Res. 642:1994;153-159.
78. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
79. Trujillo K.A. Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology. 13:1995;301-307.
80. Trujillo K.A. Are NMDA receptors involved in opiate-induced neural and behavioural plasticity? Psychopharmacology. 151:2000;121.
81. Tzschentke T.M., Schimidt W.J. N-methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats. Neurosci. Lett. 193:1995;37-40.
82. Tzschentke T.M., Schmidt W.J. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioral sensitization. Behav. Brain Res. 84:1997;99-107.
83. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56:1998;613-672.
84. Tzschentke T.M., Schmidt W.J. Effects of the non-competitive NMDA-receptor antagonist memantine on morphine- and cocaine-induced potentiation of lateral hypothalamic brain stimulation reward. Psychopharmacology. 149:2000;225-234.
85. Watanabe T., Nakagawa T., Ymamaoto R., Maeda A., Minami M., Satoh M. Involvement of glutamate receptors within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Jpn. J. Pharmacol. 4:2002;399-406.
86. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6:1996;243-251.
87. Zajaczkowski W., Quack G., Danysz W. Infusion of (+)-MK-801 and memantine-contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296:1996;239-246.